Endocan Corp Valuation
| ENDO Stock | USD 0.0001 0.00 0.00% |
Endocan Corp seems to be overvalued based on Macroaxis valuation methodology. Our model computes the value of Endocan Corp from reviewing the firm fundamentals such as Net Income of (3.31 M), price to earning of (0.09) X, and Price To Book of 18.51 X as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Endocan Corp's price fluctuation is out of control at this time. Calculation of the real value of Endocan Corp is based on 3 months time horizon. Increasing Endocan Corp's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Endocan Corp is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Endocan Pink Sheet. However, Endocan Corp's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 6.3E-5 | Hype 1.0E-4 | Naive 1.01E-4 |
The intrinsic value of Endocan Corp's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Endocan Corp's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Endocan Corp helps investors to forecast how Endocan pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Endocan Corp more accurately as focusing exclusively on Endocan Corp's fundamentals will not take into account other important factors: Endocan Corp Total Value Analysis
Endocan Corp is currently forecasted to have valuation of 1.87 M with market capitalization of 1.6 M, debt of 954.59 K, and cash on hands of 59. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Endocan Corp fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.87 M | 1.6 M | 954.59 K | 59 |
Endocan Corp Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The recent return on assets of Endocan suggests not a very effective usage of assets in December.Endocan Corp Profitability Analysis
Net Loss for the year was (3.31 M) with profit before overhead, payroll, taxes, and interest of 0.About Endocan Corp Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Endocan Corp. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Endocan Corp based exclusively on its fundamental and basic technical indicators. By analyzing Endocan Corp's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Endocan Corp's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Endocan Corp. We calculate exposure to Endocan Corp's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Endocan Corp's related companies.Thermic Sciences International develops and sells hemp based products. Thermic Sciences International was incorporated in 1969 and is based in Colorado Springs, Colorado. ENDOCAN CORP operates under Specialty Chemicals classification in the United States and is traded on OTC Exchange.
8 Steps to conduct Endocan Corp's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Endocan Corp's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Endocan Corp's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Endocan Corp's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Endocan Corp's revenue streams: Identify Endocan Corp's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Endocan Corp's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Endocan Corp's growth potential: Evaluate Endocan Corp's management, business model, and growth potential.
- Determine Endocan Corp's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Endocan Corp's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Endocan Corp Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Retained Earnings | -29.5 M | |
| Shares Float | 32.9 M |
Other Information on Investing in Endocan Pink Sheet
Endocan Corp financial ratios help investors to determine whether Endocan Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Endocan with respect to the benefits of owning Endocan Corp security.